Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031).

Por Hanson, C W, Bailer, R, Gade, E, Rode, R A, Fernandes, P B
Publicado em 1987

In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Por Stamm, J M, Hanson, C W, Chu, D T, Bailer, R, Vojtko, C, Fernandes, P B
Publicado em 1986

Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model.

Por Fernandes, P B, Hardy, D, Bailer, R, McDonald, E, Pintar, J, Ramer, N, Swanson, R, Gade, E
Publicado em 1987

Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture

Por Longo, NS, Doria-Rose, N, McKee, K, O'Dell, S, Louder, MK, Yang, Z, Bailer, R, Mascola, JR
Publicado em 2012

In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Por Fernandes, P B, Bailer, R, Swanson, R, Hanson, C W, McDonald, E, Ramer, N, Hardy, D, Shipkowitz, N, Bower, R R, Gade, E
Publicado em 1986

P16-19. Statistical design and analysis of the CAVD-VIMC Elispot transfer study 001

Por Huang, Y, Sato, A, Wood, B, Gill, D, Kochar, N, Tarragona, T, Sambor, A, Wan, H, Levine, G, Self, S, Koup, R, Cox, J, Bailer, R, Gilmour, J
Publicado em 2009

In vivo targeting of HIV gag to dendritic cells in combination with poly ICLC is safe and immunogenic in healthy volunteers

Por Caskey M, Trumpfheller C, Pollak S, Sinnenberg L, Hurley A, Pring J, Shimeliovich I, Yipp B, Anandasabapathy N, Mehandru S, Sarma P, Koup R, Bailer R, Tomaras G, Sato A, Keler T, Steinman R, Schlesinger S
Publicado em 2012-09-01

In vivo targeting of HIV gag to dendritic cells in combination with poly ICLC is safe and immunogenic in healthy volunteers

Por Caskey, M, Trumpfheller, C, Pollak, S, Sinnenberg, L, Hurley, A, Pring, J, Shimeliovich, I, Yipp, B, Anandasabapathy, N, Mehandru, S, Sarma, P, Koup, R, Bailer, R, Tomaras, G, Sato, A, Keler, T, Steinman, R, Schlesinger, S
Publicado em 2012

Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans

Por Ledgerwood, J. E., Hu, Z., Gordon, I. J., Yamshchikov, G., Enama, M. E., Plummer, S., Bailer, R., Pearce, M. B., Tumpey, T. M., Koup, R. A., Mascola, J. R., Nabel, G. J., Graham, B. S.
Publicado em 2012

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization

Por Asokan, M., Rudicell, R. S., Louder, M., McKee, K., O'Dell, S., Stewart-Jones, G., Wang, K., Xu, L., Chen, X., Choe, M., Chuang, G., Georgiev, I. S., Joyce, M. G., Kirys, T., Ko, S., Pegu, A., Shi, W., Todd, J. P., Yang, Z., Bailer, R. T., Rao, S., Kwong, P. D., Nabel, G. J., Mascola, J. R.
Publicado no J Virol (2015)

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

Por Ledgerwood, J E, Coates, E E, Yamshchikov, G, Saunders, J G, Holman, L, Enama, M E, DeZure, A, Lynch, R M, Gordon, I, Plummer, S, Hendel, C S, Pegu, A, Conan-Cibotti, M, Sitar, S, Bailer, R T, Narpala, S, McDermott, A, Louder, M, O'Dell, S, Mohan, S, Pandey, J P, Schwartz, R M, Hu, Z, Koup, R A, Capparelli, E, Mascola, J R, Graham, B S
Publicado no Clin Exp Immunol (2015)

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Por Bar, K.J., Sneller, M.C., Harrison, L.J., Justement, J.S., Overton, E.T., Petrone, M.E., Salantes, D.B., Seamon, C.A., Scheinfeld, B., Kwan, R.W., Learn, G.H., Proschan, M.A., Kreider, E.F., Blazkova, J., Bardsley, M., Refsland, E.W., Messer, M., Clarridge, K.E., Tustin, N.B., Madden, P.J., Oden, K.S., O’Dell, S.J., Jarocki, B., Shiakolas, A.R., Tressler, R.L., Doria-Rose, N.A., Bailer, R.T., Ledgerwood, J.E., Capparelli, E.V., Lynch, R.M., Graham, B.S., Moir, S., Koup, R.A., Mascola, J.R., Hoxie, J.A., Fauci, A.S., Tebas, P., Chun, T.-W.
Publicado no N Engl J Med (2016)